AI assistant
Cabaletta Bio, Inc. — Director's Dealing 2020
Dec 9, 2020
33628_dirs_2020-12-09_04b9e2c6-d9c4-4ab2-ab7d-0e2154a1b0c4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cabaletta Bio, Inc. (CABA)
CIK: 0001759138
Period of Report: 2020-12-08
Reporting Person: Nichtberger Steven (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-08 | Stock Option (Right to Buy) | $1.01 | A | 93226 | Acquired | 2028-10-28 | Common Stock (93226) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 786483 | Direct |
| Common Stock | 363000 | Indirect |
Footnotes
F1: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: On October 29, 2018, the reporting person was granted an performance stock option to purchase 279,677 shares of common stock, of which 93,226 of the shares shall vest and become exercisable upon the first dosing of a patient in a Phase 1 clinical trial for the treatment of pemphigus vulgaris. This performance criteria was met on December 8, 2020, resulting in vesting of the option as to 93,226 shares.